{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037906","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.650985+00:00","generated_at":"2026-06-04T09:11:18.946563+00:00","sec_items":["1.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Petros enters waiver/amendment with investors covering Dec 2023 equity awards and warrant terms","bullets":["Waives breach from Dec 21, 2023 issuance of 348,711 shares/options; deems them Excluded Securities.","Amends Section 4(c) of Warrants clarifying Black Scholes Value rights in Fundamental Transactions.","Waiver and Amendment effective as of December 31, 2023, entered March 21, 2024.","No additional consideration paid to investors; all holders of Preferred Stock and Warrants are party."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037906","json":"https://secwatch.observer/filing/0001104659-24-037906.json","markdown":"https://secwatch.observer/filing/0001104659-24-037906.md","text":"https://secwatch.observer/filing/0001104659-24-037906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465924037906/0001104659-24-037906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465924037906/tm249589d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:11:18.946563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"410360e324c15c188bff409ace3a0f54a6be8c39","claim":"Petros Pharmaceuticals, Inc. amended Omnibus Waiver and Amendment with the Investors (effective 2023-12-31).","evidence_excerpt":"On March 21, 2024, the Company entered into an Omnibus Waiver and Amendment (the “Waiver and Amendment”) with the Investors, effective as of December 31, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465924037906/0001104659-24-037906-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Investors"},{"label":"Effective","value":"2023-12-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}